Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Frigoli

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Journal of the American College of Cardiology|August 18, 2022
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet TherapyMarco Valgimigli, Enrico Frigoli, Pascal Vranckx, et al.
BMJ (Clinical Research Ed.)|September 29, 2016
Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trialSergio Leonardi, Enrico Frigoli, Martina Rothenbühler, et al.
Circulation|August 30, 2021
Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled TrialPieter C Smits, Enrico Frigoli, Jan Tijssen, et al.
Journal of the American College of Cardiology|September 22, 2022
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding RiskPieter C Smits, Enrico Frigoli, Pascal Vranckx, et al.
Journal of the American College of Cardiology|May 23, 2017
Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIXGiuseppe Andò, Bernardo Cortese, Filippo Russo, et al.
JACC. Cardiovascular Interventions|January 6, 2018
Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access TrialGiuseppe Gargiulo, Sara Ariotti, Pascal Vranckx, et al.
Lancet (London, England)|August 30, 2018
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trialMarco Valgimigli, Enrico Frigoli, Sergio Leonardi, et al.
The New England Journal of Medicine|August 27, 2021
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding RiskMarco Valgimigli, Enrico Frigoli, Dik Heg, et al.
American Heart Journal|February 1, 2019
Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) StudyEnrico Frigoli, Pieter Smits, Pascal Vranckx, et al.
The New England Journal of Medicine|September 2, 2015
Bivalirudin or Unfractionated Heparin in Acute Coronary SyndromesMarco Valgimigli, Enrico Frigoli, Sergio Leonardi, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Journal of the American College of Cardiology|August 18, 2022
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet TherapyMarco Valgimigli, Enrico Frigoli, Pascal Vranckx, et al.
BMJ (Clinical Research Ed.)|September 29, 2016
Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trialSergio Leonardi, Enrico Frigoli, Martina Rothenbühler, et al.
Circulation|August 30, 2021
Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled TrialPieter C Smits, Enrico Frigoli, Jan Tijssen, et al.
Journal of the American College of Cardiology|September 22, 2022
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding RiskPieter C Smits, Enrico Frigoli, Pascal Vranckx, et al.
Journal of the American College of Cardiology|May 23, 2017
Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIXGiuseppe Andò, Bernardo Cortese, Filippo Russo, et al.
JACC. Cardiovascular Interventions|January 6, 2018
Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access TrialGiuseppe Gargiulo, Sara Ariotti, Pascal Vranckx, et al.
Lancet (London, England)|August 30, 2018
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trialMarco Valgimigli, Enrico Frigoli, Sergio Leonardi, et al.
The New England Journal of Medicine|August 27, 2021
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding RiskMarco Valgimigli, Enrico Frigoli, Dik Heg, et al.
American Heart Journal|February 1, 2019
Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) StudyEnrico Frigoli, Pieter Smits, Pascal Vranckx, et al.
The New England Journal of Medicine|September 2, 2015
Bivalirudin or Unfractionated Heparin in Acute Coronary SyndromesMarco Valgimigli, Enrico Frigoli, Sergio Leonardi, et al.
Pageof 6